Biomarker analysis of plasma samples in YAMATO study: A randomized phase II trial comparing switching treatment of osimertinib following 8 months of afatinib (A) and osimertinib alone (B) in untreated advanced NSCLC patients with common EGFR mutation (TORG1939/WJOG12919L)

被引：0

作者：

Yoshioka, H. ^{[1
]}

Nakamura, A. ^{[2
]}

Sakai, K. ^{[3
]}

Nishio, K. ^{[3
]}

Yonesaka, K. ^{[4
]}

Misumi, T. ^{[5
]}

Yokoyama, T. ^{[6
]}

Itani, H. ^{[7
]}

Tachihara, M. ^{[8
]}

Kanemura, H. ^{[4
]}

Akamatsu, H. ^{[9
]}

Ono, A. ^{[10
]}

Ishikawa, H. ^{[11
]}

Yamamoto, N. ^{[9
]}

Okamoto, H. ^{[12
]}

Kurata, T. ^{[1
]}

机构：

[1] Kansai Med Univ, Dept Thorac Oncol, Hirakata, Osaka, Japan

[2] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan

[3] Kindai Univ, Fac Med, Dept Genome Biol, Osakasayama, Japan

[4] Kindai Univ, Fac Med, Dept Med Oncol, Osakasayama, Japan

[5] Natl Canc Ctr Hosp East, Dept Data Sci, Kahiwa, Japan

[6] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan

[7] Japanese Red Cross Ise Hosp, Dept Resp Med, Ise, Japan

[8] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Resp Med, Kobe, Hyogo, Japan

[9] Wakayama Med Univ, Internal Med 3, Wakayama, Japan

[10] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan

[11] Kyoto Prefectural Univ Med, Dept Mol Targeting Prevent, Kyoto, Japan

[12] Yokohama Municipal Citizens Hosp, Dept Resp Med & Med Oncol, Yokohama, Kanagawa, Japan

来源：

关键词：

D O I：

10.1016/j.annonc.2024.08.1320

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1263P

引用

页码：S809 / S809

页数：1

共 1 条